Detalle Publicación

Long noncoding RNA NIHCOLE promotes ligation efficiency of DNA double-strand breaks in hepatocellular carcinoma

Autores: Unfried Huertas, Juan Pablo; Marín-Baquero, M.; Rivera-Calzada, A.; Razquin Erro, Nerea; Martín-Cuevas, E. M.; de Bragança, S.; Aicart-Ramos, C.; McCoy, C.; Prats-Mari, L.; Arribas-Bosacoma, R.; Lee, L.; Caruso, S.; Zucman-Rossi, J.; Sangro Gómez-Acebo, Bruno Carlos; Williams, G.; Moreno-Herrero, F.; Llorca, O.; Lees-Miller, S. P.; Fortes, Puri
Título de la revista: CANCER RESEARCH
ISSN: 0008-5472
Volumen: 81
Número: 19
Páginas: 4910 - 4925
Fecha de publicación: 2021
Long noncoding RNAs (lncRNA) are emerging as key players in cancer as parts of poorly understood molecular mechanisms. Here, we investigated lncRNAs that play a role in hepatocellular carcinoma (HCC) and identified NIHCOLE, a novel lncRNA induced in HCC with oncogenic potential and a role in the ligation efficiency of DNA double-stranded breaks (DSB). NIHCOLE expression was associated with poor prognosis and survival of HCC patients. Depletion of NIHCOLE from HCC cells led to impaired proliferation and increased apoptosis. NIHCOLE deficiency led to accumulation of DNA damage due to a specific decrease in the activity of the nonhomologous end-joining (NHEJ) pathway of DSB repair. DNA damage induction in NIHCOLE-depleted cells further decreased HCC cell growth. NIHCOLE was associated with DSB markers and recruited several molecules of the Ku70/Ku80 heterodimer. Further, NIHCOLE putative structural domains supported stable multimeric complexes formed by several NHEJ factors including Ku70/80, APLF, XRCC4, and DNA ligase IV. NHEJ reconstitution assays showed that NIHCOLE promoted the ligation efficiency of bluntended DSBs. Collectively, these data show that NIHCOLE serves as a scaffold and facilitator of NHEJ machinery and confers an advantage to HCC cells, which could be exploited as a targetable vulnerability. Significance: This study characterizes the role of lncRNA NIHCOLE in DNA repair and cellular fitness in HCC, thus implicating it as a therapeutic target.